Background

Canagliflozin nova, potens, et summe selectiva sodium glucosi co-portatoris (SGLT) 2 inhibitoris [1]. Probatum est Canagliflozin excretionem glucosi urinam augere, reducendo limen glucosi renum et decrescendo glucose eliquatum re- effusio [2].

Canagliflozin ostensa est inhibere capita Na+mediatae 14C-AMG in CHO-hSGLT2, CHO rat GLT2 et CHO-mus GLT2 cum IC50 valoribus 4.4, 3.7 et 2.0 nM, respective [1].

Canagliflozin relatum est ad sanguinem Glucosum reducendum (BG) gradus dosis dependentis in utroque db/db Muribus et Zucker diabeticis pingue (ZDF) Rats. Praeterea canagliflozin probavit deminuere rationem permutationis respiratorii, et pondus corporis in DIO mures et mures ZDF [1].

Canagliflozin viva voce accipi potest [1].

Notae:
[1] Liang Y1, Arakawa K, Ueta K, Matsushita Y, Kuriyama C Martin T, Du F, Liu Y, Xu J, Conway B, Conway J, Polydori D, Mores K, Demarest K. Effectus canagliflozin in limine renum pro glucose, glycemia, et pondere corporis in exemplaribus animalis normalibus et diabeticis. PLoS PRIMUM. 2012; 7(2): e30555
[2] Sarnoski-Brocavich S, Hilas O. Canagliflozin (Invokana), agentis oralis novi generis 2 diabete. P T. 2013 Nov

Product Citation

Bahia Abbas Moussa, Marianne Alphonse Mahrouse, et al. "Diversae resolutiones technicae ad administrationem spectris imbricati: applicatio ad determinationem medicamentorum hypoglycemicorum novorum co-formatorum in compositione dosis pharmaceuticae". Spectrochimica Acta Pars A: Molecular and Biomolecular Spectroscopy Available online 20 June 2018

Chemical structure